Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Novel Coronavirus 2019

   
 
Travel Procedures and Informations
Procedures for All Incoming Passengers to Lebanon

 
 
Memos and Decisions:
 

PCR Results of Incoming Passengers:
 
 
 
Surveillance Reports
 
 
Suppressing COVID-19 Transmission
        
For the Public
Questions and Answers:

Health Tips:  
Mental health during COVID-19 outbreak

Abiding by COVID-19 Preventive Measures During Ramadan 2022

Circulars and Memorandom:



































































































 

























 









 

















































 
For the Professionals
 
 
Tuberculosis and Corona
 
 
Noncommunicable Diseases and the Corona Virus Disease 2019 (COVID-19)
 
Monitoring of COVID-19 Infection In Lebanon 
 
 
Statements
 
 
Meetings of the National Infectious Disease Committee
 
 
Laws and Regulations
مكافحة الأمراض والأوبئة
 
 

For any inquiry or clarification regarding the new coronavirus 2019-nCoV,  please contact the Ministry of Public Health on the following:

 
  • New Hotline:1787
  • Hotline for the Patient Admission to Hospitals: 01/832700
  • Service of Preventive Medicine: 01/843769 - 01/830300 Ext: 435-436-437
  • Center of the Quarantine at Beirut Airport: 01/629352
  • Epidemiological Surveillance Program: 01/614194 - 01/614196
    ...
    117
    ...
ATC Name B/G Ingredients Dosage Form Price
L01EA03 TASIGNA B Nilotinib - 200mg 200mg Capsule 412,535,139 L.L
L01EA03 NILORA G Nilotinib - 200mg 200mg Capsule, hard 122,185,399 L.L
L01EA03 TASIGNA B Nilotinib - 150mg 150mg Capsule 323,961,910 L.L
L01EA04 BOSULIF B Bosutinib - 400mg 400mg Tablet, film coated L.L
L01EA04 BOSULIF B Bosutinib - 500mg 500mg Tablet, film coated L.L
L01EA04 BOSULIF B Bosutinib - 100mg 100mg Tablet, film coated L.L
L01EA04 BOSULIF B Bosutinib - 100mg 100mg Tablet, film coated 35,663,747 L.L
L01EA04 BOSULIF B Bosutinib - 400mg 400mg Tablet, film coated 123,564,667 L.L
L01EA04 BOSULIF B Bosutinib - 500mg 500mg Tablet, film coated 154,453,246 L.L
L01EA05 ICLUSIG B Ponatinib - 15mg 15mg Tablet, film coated 103,555,839 L.L
L01EA05 ICLUSIG B Ponatinib - 45mg 45mg Tablet, film coated 207,092,651 L.L
L01EB01 IRESSA B Gefitinib - 250mg 250mg Tablet, fim coated 135,027,509 L.L
L01EB01 APO-GEFITINIB G Gefitinib - 250mg 250mg Tablet 87,345,820 L.L
L01EB01 GEFITINIB ARROW G Gefitinib - 250mg 250mg Tablet, coated 85,330,070 L.L
L01EB01 GEFITINIB BIOGARAN G Gefitinib - 250mg 250mg Tablet, coated 87,070,893 L.L
L01EB01 GEFITINIB BIOGARAN G Gefitinib - 250mg 250mg Tablet, coated L.L
L01EB01 GEFITINIB ARROW G Gefitinib - 250mg 250mg Tablet, coated L.L
L01EB02 APO-ERLOTINIB G Erlotinib (HCl) - 100mg 100mg Tablet 79,672,726 L.L
L01EB02 MIRATA G Erlotinib (HCl) - 100mg 100mg Tablet, film coated 77,379,009 L.L
L01EB02 TARESSA 100 G Erlotinib (HCl) - 100mg 100mg Tablet, film coated 82,247,256 L.L
L01EB02 APO-ERLOTINIB G Erlotinib (HCl) - 150mg 150mg Tablet 91,523,229 L.L
L01EB02 MIRATA G Erlotinib (HCl) - 150mg 150mg Tablet, film coated 88,599,923 L.L
L01EB02 TARESSA 150 G Erlotinib (HCl) - 150mg 150mg Tablet, film coated 98,617,813 L.L
L01EB04 TAGRISSO B Osimertinib - 80mg 80mg Tablet, film coated L.L
L01EB04 TAGRISSO B Osimertinib - 80mg 80mg Tablet, film coated 603,192,941 L.L
L01EC01 ZELBORAF B Vemurafenib - 240mg 240mg Tablet, film coated L.L
L01EC01 ZELBORAF B Vemurafenib - 240mg 240mg Tablet, film coated 142,041,587 L.L
L01EC03 BRAFTOVI BioTech Encorafenib - 50mg 50mg Capsule, hard 70,084,833 L.L
L01EC03 BRAFTOVI BioTech Encorafenib - 75mg 75mg Capsule, hard 149,227,143 L.L
L01ED01 XALKORI B Crizotinib - 250mg 250mg Capsule L.L
    ...
    117
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2026